Abstract: An opening-and-closing body driving device includes an extendable unit including a spindle, a nut, a rod, a bearing, and a guide tube; and a driving unit. The guide tube includes an insertion portion, and an inner tube configured to allow movement of the nut in the axial direction and restrict rotation of the nut. A surface of the bearing facing a direction opposite to an insertion direction, in which the insertion portion is inserted, is defined as a first reference surface, and a surface of the housing facing a direction opposite to the insertion direction is defined as a second reference surface. A distance from the first reference surface of the bearing to a distal end of the inner peripheral wall is longer than a distance from the second reference surface of the housing to a distal end of the outer peripheral wall in the axial direction.

Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Abstract: A sliding device configured to perform a sliding process on a surface of an object to be slid includes a sliding part including sliding bodies each having a flat working surface; a first driving mechanism configured to regularly move the sliding bodies in parallel with the working surfaces of the sliding bodies; and a second driving mechanism configured to regularly move the sliding part in parallel with the working surfaces in a direction different from a moving direction by the first driving mechanism while the first driving mechanism moves the sliding bodies. This enables uniform supply of the sliding process material onto the surface of the object to be slid or clean the surface of the object to be slid.

Abstract: A method for supplying a sliding process material to or removing it from a surface of an object to be slid using a sliding part including a plurality of sliding bodies each having a flat working surface, the sliding part is regularly moved, preferably by a second driving mechanism, in parallel with the working surfaces of the sliding bodies and in a direction different from a moving direction of the sliding bodies while the sliding bodies are regularly moved, preferably by a first driving mechanism, in parallel with the working surfaces. This configuration uniformly supplies the sliding process material to the surface of the object to be slid.

Abstract: To prevent defects in microparticles from occurring in a case of arraying the microparticles having a diameter of less than or equal to 50 ?m on a base material. Provided is a microparticle arraying mask for arraying microparticles having a diameter of less than or equal to 50 ?m on a base material. The microparticle arraying mask has through-holes into which the microparticles are inserted. An opening plane of the through-holes on a microparticle supply side has an area smaller than an area of an opening plane of the through-holes on a microparticle discharge side. In a case of assuming that a direction from the opening plane on the microparticle supply side to the opening plane on the microparticle discharge side is a positive direction of a z-axis, and a sectional area of the through-holes vertical to the z-axis is A, dA(z)/dz>0 holds in a whole region in the through-holes along the z-axis, and Expression (1) below is satisfied: 0.4?t/d?1.0??(1).

Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.

Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

Abstract: Disclosed is a terminal box with improved tab wire connection strength with limited warping and breakage of a translucent insulation substrate. A solar cell module is provided with: a solar cell with a cathode and an anode positioned on one surface thereof; a pair of power extraction tab wires which are connected onto the cathode and anode of the solar cell with a conductive adhesive layer interposed therebetween; and a pair of terminal box tab wires which are disposed on one surface of the solar cell with an insulating adhesive layer interposed therebetween, one end thereof being positioned on the cathode and the anode and which connect a terminal box with the pair of power extraction tab wires. The power extraction tab wires on the cathode and the anode are connected to the one end of the terminal box tab wires with the conductive adhesive layer interposed therebetween.

Abstract: To ensure connection reliability between a tab wire for a collector and a tab wire for a terminal box over a long period of time. This solar cell module is provided with: a solar cell, on one surface of which an electrode is arranged; and a tab wire, which includes a collector tab unit that is connected onto the electrode of the solar cell with a connection layer interposed therebetween and a terminal box tab unit that is provided on one surface of the solar cell with an insulating layer interposed therebetween, and in this structure, the collector tab unit and the terminal box tab unit are continuously formed via a folded part.

Abstract: Disclosed is a solar cell module in which a reduction in the adhesive strength of the sealing resin used is suppressed even after use in a severe environment for a long period of time, in which corrosion of an electrode is prevented, and which has favorable flame resistance. The solar cell module uses, as the sealing resin, a blended polymer of a thermoplastic ester polyol polyurethane resin including an ester-based polyol unit and a thermoplastic ether polyol polyurethane resin including an ether-based polyol unit. The blending mass ratio of the thermoplastic ester polyol polyurethane resin to the thermoplastic ether polyol polyurethane resin in the blended polymer is 10:90 to 50:50. The thermoplastic ether polyol polyurethane resin includes a polyurethane resin A having flame resistance and a polyurethane resin B having lower flame resistance but higher adhesion properties than the polyurethane resin A.

Abstract: A solar cell module is manufactured by resin-sealing a solar cell having a surface electrode to which a tab wire is connected, a tab wire is connected to the surface electrode and the solar cell is sealed with a sealing resin at a relative low temperature during the resin sealing step. For such purposes, a thin-film solar cell having a surface electrode to which a tab wire is connected is resin-sealed with a conductive adhesive film by using a decompression laminator, whereby the thin-film solar cell module is manufactured. A decompression laminator having a first chamber and a second chamber partitioned by a flexible sheet is used. Each chamber is capable of independent internal pressure adjustment. The second chamber includes a heating stage capable of heating. A resin mutually compatible with the thermoplastic resin constituting the conductive adhesive film is used as the sealing resin.

Abstract: Provided are a compound represented by Formula (I): wherein R1, R2, R3, and R4 are each independently selected from a hydrogen atom, a C1-6 alkyl group which may be substituted, a C7-14 aralkyl group which may be substituted and —C(?O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f). or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Abstract: A solar cell module includes a glass substrate, a first sealing resin layer, a solar cell connected to a tab wire, a second sealing resin layer, and a protective sheet, which are laminated. The second sealing resin layer is formed from a blend polymer of a thermoplastic polyurethane resin having an ester-type polyol unit and a thermoplastic polyurethane resin having an ether-type polyol unit. The blend ratio of the thermoplastic polyurethane resin having the ester-type polyol unit to the thermoplastic polyurethane resin having the ether-type polyol unit in the blend polymer is 20:80 to 50:50 by mass.

Abstract: A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity.

Abstract: The invention provides a glucitol derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): wherein m is an integer selected among 1-3; R1 to R4 each independently is optionally substituted alkyl, etc.; Ar1 is optionally substituted naphthyl; and A is optionally substituted heteroaryl, a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, and the like each containing the compound.

Abstract: Provided are a compound represented by Formula (I): wherein R1, R2, R3, and R4 are each independently selected from a hydrogen atom, a C1-6 alkyl group which may be substituted, a C7-14 aralkyl group which may be substituted and —C(?O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f). or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a compound of Formula (I): wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, an optionally substituted C1-C6 alkyl group, an optionally substituted C7-C14 aralkyl group and —C(?O)Rx; Rx represents an optionally substituted C1-C6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted C1-C6 alkoxy group or —NReRf; Ar1 represents an optionally substituted aromatic carbocyclic ring or an optionally mono-substituted aromatic heterocyclic ring; Q represents —(CH2)m-(L)p- or -(L)p-(CH2)m—; m represents an integer selected from 0 to 2, n represents an integer selected from 1 and 2, and p represents an integer selected from 0 and 1; L represents —O—, —S— or —NR5—; and A represents an optionally substituted aryl group or an optionally substituted heteroaryl group, a prodrug thereof and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical preparation or pharmaceutical co

Abstract: The present invention relates to methods of treatment of certain metabolic diseases, and to the use of compounds and their prodrugs, and/or pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds useful in treating such diseases. In particular, the invention relates to the use of compounds and compositions for treatment of cardiovascular diseases, diabetes, cancers, acidosis, and obesity through the inhibition of malonyl-CoA decarboxylase (MCD). These compounds have the following formulae: (I) and (II) Wherein Y, C, R1, R2, R6, and R7 are defined herein.